Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: January 5, 2026
Contraceptive Antibody ZB-06 Vaginal MPT Film

HC4-N, KB15A

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Boston University, ZabBio, KBio, Magee-Womens Research Institute, Eastern Virginia Medical School
Active
Last updated: January 5, 2026
Combined Copper and Metal IUDs

Cu-Mg IUD, Cu-Zn IUD, Cu-Fe IUD

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Peking University, China National Research Institute for Family Planning, University of Technology Sydney, University of Maryland
Inactive
Last updated: January 5, 2026
Chongqing Uterine-Shaped IUD

Copper-Plated Uterine Cavity-Shaped IUD (UCDcu), UCu300 IUD

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Intrauterine
  • Intended Duration: Long-Acting
  • Development Stage: Single-Country Approval
  • Developer(s)/Researcher(s): Chongqing Medical Equipment Factory Co., Ltd.
Active
Last updated: January 5, 2026
Centchroman

Ormeloxifene

  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Short-Acting
  • Development Stage: Phase IV
  • Developer(s)/Researcher(s): King George's Medical University, India Health Action Trust, Central Drug Research Institute, India, HLL Lifecare Limited
Active
Last updated: January 5, 2026
CDK2 Inhibitors

EF-4-177

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of Minnesota, Università di Palermo
Active
Last updated: January 5, 2026
Cabotegravir Pellet Implant with Levonorgestrel

CAB + LNG Pellet

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): CONRAD
Active
Last updated: January 5, 2026
BRDT Inhibitors

JQ1, NHWD870, CDD-1102

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Cornell University, Baylor College of Medicine, Nantong University, Sichuan University, University of Minnesota
Active
Last updated: January 5, 2026
Annovera™

Nestorone + Ethinyl Estradiol One-Year Contraceptive Vaginal Ring, NES + EE Vaginal Ring

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Long-Acting
  • Development Stage: Single-Country Approval
  • Developer(s)/Researcher(s): Population Council, NICHD, WHO, NIH, Gates Foundation, Avis and Clifford Barrus Medical Foundation, TherapeuticsMD
Active
Last updated: January 5, 2026
ADAM Vas-Occlusive Device

ADAM Air

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Vas Deferens
  • Intended Duration: Long-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Contraline, LLC